BeiGene Regains Full Rights to Tislelizumab After Terminating Novartis Deal
China-based biotech company BeiGene (NASDAQ: BGNE) has reached a mutual agreement with Novartis (NYSE: NVS)...
NASDAQ: BGNE
Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...
Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth
China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...
BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023
BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...
Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...
BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA
China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...
Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...
CDE Indicates Priority Review for Overland ADCT’s Zynlonta and BeiGene’s Brukinsa
The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)...
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...
BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...
Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...
BeiGene’s Tislelizumab Approved in China for First-Line Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has been approved...
BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients
China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...